Aug 16, 2018 Evoke Pharma`s GimotiTM NDA Accepted for FDA Review PDF Version April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company`s 505(b)(2) New Drug Application (NDA) for GimotiTM, the Company`s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis, has been accepted for review by the U.S. Food and Drug Administration (FDA). In its Filing Communication/Day-74 letter, FDA stated that the...
|
